Moreover, Reisländer et al. [144] have revealed that the treatment of BRCA1- or BRCA2-deficient CRC cell lines with olaparib boosted the up-regulation of innate immune response genes upon intrinsically high levels of DNA damage [144]. This evidence concerns the gene BRCA1 and colorectal carcinoma.